Vivace Therapeutics disclosed preclinical efficacy for VT‑3989, a TEAD inhibitor that suppressed growth of aggressive NF2‑deficient meningioma models and other TEAD‑driven tumors. Data included both in vitro and in vivo models and support early clinical development for advanced solid tumors, including mesothelioma indications. The program targets the YAP/TAZ‑TEAD transcriptional axis, a pathway implicated in NF2 loss and several hard-to-treat tumors. For translational teams: TEAD inhibitors require careful biomarker strategies (NF2 status, TEAD activity) and safety monitoring given the pathway’s role in normal tissue homeostasis.